In a filing, CRISPR Therapeutics AG revealed its Director George Simeon acquired Company’s shares for reported $51.5 million on Jul 16 ’25. In the deal valued at $52.03 per share,989,812 shares were bought. As a result of this transaction, George Simeon now holds 1,730,179 shares worth roughly $113.03 million.
Then, Patel Naimish sold 3,932 shares, generating $141,316 in total proceeds. Upon selling the shares at $35.94, the Chief Medical Officer now owns 6,068 shares.
Before that, Kulkarni Samarth sold 10,031 shares. CRISPR Therapeutics AG shares valued at $413,578 were divested by the Chief Executive Officer at a price of $41.23 per share. As a result of the transaction, Kulkarni Samarth now holds 195,085 shares, worth roughly $12.74 million.
Evercore ISI upgraded its CRISPR Therapeutics AG [CRSP] rating to an Outperform from a an In-line in a research note published on February 14, 2025; the price target was increased to $99 from $60. A number of analysts have revised their coverage, including TD Cowen’s analysts, who increased its forecast for the stock in mid February from “a Sell” to “a Hold”. H.C. Wainwright began covering CRSP with “Buy” recommendation on February 03, 2025. Needham maintained its rating on August 06, 2024. It rated CRSP as “a Buy”.
Price Performance Review of CRSP
On Monday, CRISPR Therapeutics AG [NASDAQ:CRSP] saw its stock jump 0.31% to $65.33. Over the last five days, the stock has gained 15.79%. CRISPR Therapeutics AG shares have risen nearly 8.02% since the year began. Nevertheless, the stocks have risen 65.98% over the past one year.
How much short interest is there in CRISPR Therapeutics AG?
A steep rise in short interest was recorded in CRISPR Therapeutics AG stocks on 2025-06-13, growing by 0.34 million shares to a total of 21.41 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 21.07 million shares. There was a rise of 1.61%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 02, 2024 when Rodman & Renshaw began covering the stock and recommended ‘”a Buy”‘ rating along with a $90 price target.
